Literature DB >> 9534038

Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease.

D S Cooper1.   

Abstract

Therapy for Graves' disease is not straightforward and often involves complex decision making. Long-term antithyroid drug therapy is appealing because it is nonablative, but it is not for everyone. The physician must weigh the advantages and disadvantages of antithyroid drug treatment and help the patient arrive at an individualized therapeutic strategy that is appropriate and cost-effective.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9534038     DOI： 10.1016/s0889-8529(05)70308-x

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  13 in total

1.  Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.

Authors:  E Mazza; M Carlini; D Flecchia; A Blatto; O Zuccarini; S Gamba; S Beninati; M Messina
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

2.  Total thyroidectomy in Basedow-Graves' disease treatment: our experience.

Authors:  M Barbuscia; A Querci; A Tonante; D Paparo; F Taranto; A Ilacqua; E Gagliano; A Milone
Journal:  G Chir       Date:  2015 May-Jun

Review 3.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

4.  Does smoking increase relapse rates in Graves' disease?

Authors:  L E Kimball; E Kulinskaya; B Brown; C Johnston; N R Farid
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 5.  Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review.

Authors:  F Azizi; H Abdi; L Mehran; A Amouzegar
Journal:  J Endocrinol Invest       Date:  2022-01-28       Impact factor: 4.256

Review 6.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

7.  Methimazole upregulates T-cell-derived cytokines without improving the existing Th1/Th2 imbalance in Graves' disease.

Authors:  T Kocjan; B Wraber; A Kocijancic; S Hojker
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

8.  Comparison of methimazole/hydrocortisone ointment with oral methimazole in patients with graves disease: A prospective, randomized, open-label, parallel-group, 18-month study.

Authors:  Ling Chen; Hong-Qing Wang; Yan-Yan Gao; Jun Liang; Men Wang; Jie Bai; Wen-Bo Qi; Jun-Sheng Zhang; Jian Zhang; Juan-Qing Ren; Hui-Qing Li
Journal:  Curr Ther Res Clin Exp       Date:  2008-08

Review 9.  Surgical treatment of Graves' disease: evidence-based approach.

Authors:  Peter Stålberg; Anna Svensson; Ola Hessman; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

10.  Peripheral blood lymphocyte apoptosis and its relationship with thyroid function tests in adolescents with hyperthyroidism due to Graves' disease.

Authors:  Maria Klatka; Ewelina Grywalska; Agata Surdacka; Jerzy Tarach; Janusz Klatka; Jacek Roliński
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.